REGENXBIO’s (RGNX) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX) in a research report report published on Thursday morning,Benzinga reports. The firm currently has a $52.00 price objective on the biotechnology company’s stock.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Leerink Partners upped their price objective on REGENXBIO from $16.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Royal Bank Of Canada raised their price objective on REGENXBIO from $17.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Wall Street Zen upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Monday, November 24th. Finally, HC Wainwright restated a “buy” rating and issued a $34.00 price target on shares of REGENXBIO in a report on Tuesday, October 7th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.00.

REGENXBIO Price Performance

RGNX stock opened at $11.60 on Thursday. REGENXBIO has a 1-year low of $5.03 and a 1-year high of $16.19. The business has a 50-day moving average price of $13.74 and a 200 day moving average price of $11.29. The company has a market capitalization of $587.19 million, a P/E ratio of -3.34 and a beta of 1.07.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) EPS for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.18. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. The business had revenue of $29.73 million for the quarter, compared to the consensus estimate of $24.41 million. On average, analysts anticipate that REGENXBIO will post -4.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Voss Capital LP raised its position in REGENXBIO by 47.4% during the 2nd quarter. Voss Capital LP now owns 575,000 shares of the biotechnology company’s stock worth $4,721,000 after buying an additional 185,000 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of REGENXBIO by 23.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 705,403 shares of the biotechnology company’s stock valued at $6,807,000 after acquiring an additional 132,942 shares during the last quarter. Squarepoint Ops LLC increased its stake in shares of REGENXBIO by 2,049.0% in the second quarter. Squarepoint Ops LLC now owns 219,288 shares of the biotechnology company’s stock worth $1,800,000 after acquiring an additional 209,084 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of REGENXBIO during the second quarter worth $1,453,000. Finally, 22NW LP lifted its position in REGENXBIO by 38.1% during the second quarter. 22NW LP now owns 923,679 shares of the biotechnology company’s stock valued at $7,583,000 after purchasing an additional 255,000 shares during the period. Hedge funds and other institutional investors own 88.08% of the company’s stock.

Key Stories Impacting REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Chardan Capital reaffirmed a “buy” rating and set a $52 price target, a bullish research note that likely supported short‑term buying interest. Chardan buy rating (Benzinga)
• Neutral Sentiment: Trading has been heavier than normal since the FDA news, producing a bounce as investors priced in both risk and potential longer‑term value; elevated volume can amplify moves in either direction. Market reaction and volume (Benzinga)
• Negative Sentiment: The U.S. FDA has placed clinical holds on REGENXBIO’s RGX‑111 (MPS I) and RGX‑121 (MPS II) programs after a brain tumor was identified in a treated participant — a major regulatory setback that increases uncertainty around timelines, data review outcomes and program viability. FDA clinical hold (Reuters) Company regulatory update (PR Newswire)
• Negative Sentiment: Several law firms have opened investigations into whether REGENXBIO adequately disclosed safety issues and the facts leading to the FDA holds; potential litigation or disclosure liabilities add pressure on sentiment and could be follow‑on catalysts. Levi & Korsinsky investigation (Newsfile) Holzer & Holzer investigation (GlobeNewswire)
• Negative Sentiment: News coverage has framed the FDA action as a material adverse development, and several outlets reported sharp intraday declines earlier in the week — evidence that sentiment is fragile and the stock remains susceptible to headline risk. Coverage of price drop (Investing.com)

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.